Stock AnalizScholar Rock Holding Corp SRRK
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Scholar Rock Holding Corp (SRRK) is a healthcare company listed in the US with a market value of about $5.3B. In the twelve months to September 30, 2026 it had revenue of $570000 and net income of -$414M, a net margin of -72563.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -50%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570000 | $0 | — | — | $33M | $19M | $15M | $20M | $0 | — |
| Net income | -$414M | -$378M | -$246M | -$166M | -$135M | -$132M | -$86M | -$51M | -$49M | -$25M |
| Free cash flow | -$310M | -$301M | -$201M | -$145M | -$134M | -$132M | -$64M | -$66M | $23M | -$22M |
| EPS (diluted) | $-3.23 | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 | $-2.81 | $-1.85 | $-3.15 | $-15.30 |
| Net margin | -72563.2% | — | — | — | -405.2% | -700.5% | -561.5% | -248.9% | — | — |
| ROIC | — | -85.7% | -45.9% | -47.0% | -32.1% | -40.9% | -21.5% | -36.4% | -37.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $70.44, 63% above the current price; targets range from $58.00 to $84.00; the consensus rating is “Strong buy”; expected EPS is $-3.03 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Scholar Rock Holding pay a dividend?
Not currently.
Is Scholar Rock Holding a good stock to buy?
We do not give buy or sell advice. Scholar Rock Holding scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.